Streetbeat News

Earnings

BIOL

Biolase (NASDAQ:BIOL) is scheduled to release its quarterly earnings report on March 21, 2024, with an estimated EPS of $-2.55. The company's past earnings performance shows a pattern of not meeting EPS estimates, leading to significant share price drops the following day. Shares are currently trading at $0.14, reflecting a 99.59% decrease over the last 52 weeks. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 5:00 pm

NOW

In the last three months, 21 analysts have provided diverse ratings on ServiceNow (NYSE:NOW), with an average 12-month price target of $840.76, marking a 12.5% increase from the previous target. The ratings range from bullish to bearish, with the majority being bullish. ServiceNow's financial performance shows a revenue growth of 25.62%, a net margin of 12.11%, and strong ROE and ROA figures, indicating robust financial health and management efficiency.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 5:00 pm

TKC

Turkcell Iletisim Hizmetleri (TKC) reported its FY23 earnings per share (EPS) at TRY2.9, an increase from TRY2.8 year-over-year. The company's revenue also rose to TRY108.599 million from TRY93.486 million in the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 4:59 pm

PUK

Prudential plc (NYSE:PUK) shares fell after reporting FY 2023 results with increased insurance revenue, new business profit, and adjusted operating profit. The company also raised its dividend, reflecting positive financial and operational performance and strategic progress.

Portfolio Pulse from Lekha Gupta

March 20, 2024 | 4:53 pm

MU

Micron Technology, Inc. (NASDAQ:MU) is set to release its Q2 earnings after the market closes on March 20, 2024. Analysts predict a loss of 26 cents per share and revenue of $5.33 billion. The company recently started volume production of its HBM3E solution. Shares increased by 0.2% to $94.00. Analysts from UBS, Cantor Fitzgerald, TD Cowen, Citigroup, and Wedbush have updated their ratings and price targets for Micron, with targets ranging from $103 to $150.

Portfolio Pulse from Avi Kapoor

March 20, 2024 | 4:47 pm

AQST

ETAO

LFCR

SIG

TRUG

XTLB

U.S. stocks were mostly flat as markets awaited the Federal Reserve's interest rate decision. Industrials shares rose by 0.5%, while energy shares fell by 0.6%. Crude oil inventories in the U.S. declined, contrary to market expectations. ETAO International announced a reverse stock split, XTL Biopharmaceuticals plans to acquire The Social Proxy, and TruGolf Holdings expanded its AI technology licensing agreement. Lifecore Biomedical concluded its strategic evaluation, Aquestive Therapeutics priced a public offering, and Signet Jewelers reported disappointing sales and guidance.

Portfolio Pulse from Avi Kapoor

March 20, 2024 | 4:47 pm

WULF

TeraWulf, Inc. (NASDAQ:WULF) shares rose after reporting Q4 financial results, with a significant increase in self-mining capacity and Bitcoin production, despite missing earnings and sales estimates. The company aims to expand its mining capacity and explore HPC and AI applications. Cantor Fitzgerald maintained a $4 price target.

Portfolio Pulse from Erica Kollmann

March 20, 2024 | 4:44 pm

WULF

TeraWulf's stock price increased due to a rise in Bitcoin value and the company's announcement of its Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 4:43 pm

SLRN

Acelyrin Inc (NASDAQ:SLRN) released positive Phase 1/2 trial data for lonigutamab in thyroid eye disease, showing rapid improvements in symptoms with no serious adverse events. A Phase 2b/3 trial is planned for the second half of 2024. SLRN shares rose 6.53% to $8.48.

Portfolio Pulse from Vandana Singh

March 20, 2024 | 4:34 pm

TIGR

UP Fintech Holding Limited (NASDAQ:TIGR) reported its fourth-quarter FY23 results, showing a mixed financial performance. Total revenues increased by 9.6% year-over-year to $70.0 million, but total net revenues decreased by 4.7% to $54.0 million. The company saw a decline in commissions by 11.9% due to decreased trading volume, but interest income rose by 31.3% on higher margin financing and securities lending activities. UP Fintech added 39,034 new funded accounts, a 42.8% increase year-over-year, and the total account balance rose by 118.5% to $30.6 billion. However, non-GAAP net income per ADS was $0.007, missing the consensus of $0.07. The company also announced the introduction of the Combo Option Strategy feature and an upgrade to its Type 1 License by the Hong Kong SFC, allowing it to offer Virtual Asset dealing services to Professional Investors. Despite these developments, TIGR shares are down by 10.1% at $4.02.

Portfolio Pulse from Lekha Gupta

March 20, 2024 | 4:10 pm